Skip to search formSkip to main contentSkip to account menu
Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study.
View on PubMed
The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement
TLDR
This management guideline summarises current knowledge on the prevention, diagnosis and treatment of TB related to solid organ and hematopoietic stem cell transplantation and provides an expert consensus on questions where scientific evidence is still lacking.
View on Publisher
A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis.
TLDR
A randomized, open-label, phase II trial that compared the safety and efficacy of intravenous amphotericin B deoxycholate with that of AmB among HIV-positive patients with central nervous system cryptococcosis finds that AmB plus fluconazole administered at a dosage of 800 mg for 14 days, followed by flu Conazole alone at the randomized dosage for 56 days, is well-tolerated and efficacious.
View on PubMed
Cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis: a prospective multicenter study.
TLDR
No association between the timing of HAART initiation and the diagnosis of IRIS was identified, and increased baseline serum cryptococcal antigen (CrAg) titer was a risk factor for IRIS.
View on PubMed
Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study.
TLDR
This assay may be useful to predict if patients are at low, intermediate, or high risk for the development of subsequent CMV disease after prophylaxis.
View on PubMed
Histoplasmosis after solid organ transplant.
TLDR
Although late cases occur, the first year after SOT is the period of highest risk for histoplasmosis, in patients who survive the first month after diagnosis, treatment with an amphotericin formulation followed by an azole for 12 months is usually successful, with only rare relapse.
View on PubMed
Randomized, Double‐Blind Trial of Anidulafungin Versus Fluconazole for Prophylaxis of Invasive Fungal Infections in High‐Risk Liver Transplant Recipients
TLDR
Anidulafungin and fluconazole have similar efficacy for antifungal prophylaxis in most liver transplant recipients and may be beneficial if the patient has an increased risk for Aspergillus infection or received flu Conazole before transplantation.
View on Wiley
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.
TLDR
The data do not support a role for initial, adjunctive deferasirox therapy for mucormycosis, and population imbalances in this small Phase II study make generalizable conclusions difficult.
View on PubMed
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management.
TLDR
Overall, in clinical trials, VZV rates of infection were low but higher with fingolimod compared with placebo, and a similar rate was confirmed in the ongoing extension studies.
View on PubMed
COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literature
View on Elsevier
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License